During the European Congress of Radiology, ECR2023, global medical imaging AI firm Oxipit announced that its diagnostic solutions will be available on the CARPL platform. Photo credit: Getty Images
March 3, 2023 — Oxipit, a creator of AI tools for global medical imaging, has announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality for real-time quality assurance and ChestEye for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company’s products, according to a statement released on the partnership. Both companies are participating at the European Congress of Radiology (ECR2023), held March 1-5 in Vienna, Austria.
CARPL connects AI developers and healthcare providers improving access, affordability and quality of medical care globally. The company explained it is an end-to-end technology platform for the testing, distribution and deployment of medical imaging AI in clinical practice. As such, CARPL bridges the gap between healthcare AI application providers and clinicians by being a one-stop solution to access, assess, and adopt AI solutions.
According to Gediminas Peksys, CEO of Lithuania-based Oxipit, “CARPL is our long-term partner for research and client deployments. It is a future savvy organization, quick to pick up the latest diagnostic innovations. With the CARPL platform, we may present our products within easy reach of a global medical audience.”
Dr. Vasanth Venugopal, Chief Medical Officer and Clinical Product Lead at CARPL.ai, said this of the partnership: “With the formalization of our partnership, strengthened by CARPL's capabilities to deploy AI solutions at scale across institutions and Oxipit's robust set of quality audit and autonomous solutions, we envision a future full of infinite possibilities to revolutionize radiology practice.” He further noted, “Oxipit’s CE approval for autonomous reporting of normal chest X-rays is a landmark achievement that “had forever changed the perception and potential of AI applications in radiology.”
The full Oxipit product portfolio will be offered on the CARPL platform, helping medical institutions to increase reporting efficiency, addressing radiologist shortages and improving diagnostic quality. The company summarized its AI solutions, noting:
ChestLink is the first autonomous AI application to receive a CE Class IIb certification. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. By autonomously reporting on healthy patient chest X-rays, ChestLink can automate 15-40% of daily reporting workflow depending on the type of medical institution.
Oxipit Quality acts as an AI-powered second-reader for diagnostic quality assurance. By analyzing medical images and corresponding radiologist reports, the application can detect diagnostic mistakes in real-time. If the platform detects an unreported finding, it instantly notifies the radiologist to take another look at the study. Oxipit Quality works with chest and MSK X-rays, MMG images and CT scans.
ChestEye is an AI-powered CAR application with support for 75 radiological findings. The application includes preliminary reporting and triage features. ChestEye serves as the first step for diagnostic AI adoption, with clients then being able to move automation or quality assurance depending on their usage scenario.
More information:
Related content:
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
Oxipit and AstraZeneca Join Forces to Aid Early Lung Cancer Detection
June 05, 2025 
